Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease

Autores
Sosa-Estani, Sergio; Segura, Elsa L.; Ruiz, Andrés Mariano; Velazquez, Elsa; Porcel, Betina Mabel; Yampotis, Cristina
Año de publicación
1998
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
A double-blind, randomized, clinical field trial was designed to test the efficacy and tolerance of a specific drug treatment in children in the indeterminate phase of infection by Trypanosoma cruzi. Children were treated with benznidazole at a dose of 5 mg/kg/day for 60 days or placebo and followed-up for 48 months. The treated children showed a significant decrease in geometric mean titers of antibodies against T. cruzi measured by indirect hemagglutination, indirect immunofluorescence, and ELISA. After a four year follow-up, 62% of the benznidazole- treated children and no placebo-treated child were seronegative for T. cruzi when tested by an ELISA using a T. cruzi flagellar calcium-binding protein (F29). Xenodiagnosis carried out after 48 months of follow-up was positive in 4.7% of the benznidazole-treated children and in 51.2% of the placebo-treated children. These results show the tolerance to and efficacy of benznidazole against T. cruzi in seropositive children six to 12 years of age. We used an early serologic marker of cure after treatment, consisting of a recombinant antigen implemented in a rapid, conventional serologic procedure.
Fil: Sosa-Estani, Sergio. ANLIS Dr.C.G.Malbrán. Centro Nacional de Diagnóstico e Investigación en Endemo-Epidemias; Argentina.
Fil: Segura, Elsa Leonor. ANLIS Dr.C.G.Malbrán; Argentina.
Fil: Ruiz, Andres Mariano. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología Dr. Mario Fatala Chaben; Argentina.
Fil: Velazquez, Elsa. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología Dr. Mario Fatala Chaben; Argentina.
Fil: Porcel, Betina Mabel. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología Dr. Mario Fatala Chaben; Argentina.
Fil: Yampotis, Cristina. Hospital San Roque; Argentina.
Fuente
The American Journal of Tropical Medicine and Hygiene, 1998, 59(4), 526–529.
Materia
Enfermedad de Chagas
Nitroimidazoles
Tripanocidas
Método Doble Ciego
Niño
Nivel de accesibilidad
acceso abierto
Condiciones de uso
Repositorio
Sistema de Gestión del Conocimiento ANLIS MALBRÁN
Institución
Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
OAI Identificador
oai:sgc.anlis.gob.ar:Publications/123456789/241
Acceder
id SGCANLIS_fc97c21a8e000a12c5218da44e66f3d0
oai_identifier_str oai:sgc.anlis.gob.ar:Publications/123456789/241
network_acronym_str SGCANLIS
repository_id_str a
network_name_str Sistema de Gestión del Conocimiento ANLIS MALBRÁN
spelling Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' diseaseSosa-Estani, SergioSegura, Elsa L.Ruiz, Andrés MarianoVelazquez, ElsaPorcel, Betina MabelYampotis, CristinaEnfermedad de ChagasNitroimidazolesTripanocidasMétodo Doble CiegoNiñoA double-blind, randomized, clinical field trial was designed to test the efficacy and tolerance of a specific drug treatment in children in the indeterminate phase of infection by Trypanosoma cruzi. Children were treated with benznidazole at a dose of 5 mg/kg/day for 60 days or placebo and followed-up for 48 months. The treated children showed a significant decrease in geometric mean titers of antibodies against T. cruzi measured by indirect hemagglutination, indirect immunofluorescence, and ELISA. After a four year follow-up, 62% of the benznidazole- treated children and no placebo-treated child were seronegative for T. cruzi when tested by an ELISA using a T. cruzi flagellar calcium-binding protein (F29). Xenodiagnosis carried out after 48 months of follow-up was positive in 4.7% of the benznidazole-treated children and in 51.2% of the placebo-treated children. These results show the tolerance to and efficacy of benznidazole against T. cruzi in seropositive children six to 12 years of age. We used an early serologic marker of cure after treatment, consisting of a recombinant antigen implemented in a rapid, conventional serologic procedure.Fil: Sosa-Estani, Sergio. ANLIS Dr.C.G.Malbrán. Centro Nacional de Diagnóstico e Investigación en Endemo-Epidemias; Argentina.Fil: Segura, Elsa Leonor. ANLIS Dr.C.G.Malbrán; Argentina.Fil: Ruiz, Andres Mariano. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología Dr. Mario Fatala Chaben; Argentina.Fil: Velazquez, Elsa. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología Dr. Mario Fatala Chaben; Argentina.Fil: Porcel, Betina Mabel. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología Dr. Mario Fatala Chaben; Argentina.Fil: Yampotis, Cristina. Hospital San Roque; Argentina.1998info:ar-repo/semantics/articuloinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdf1476-1645http://sgc.anlis.gob.ar/handle/123456789/241http://www.ajtmh.org/content/59/4/526.full.pdf+htmlThe American Journal of Tropical Medicine and Hygiene, 1998, 59(4), 526–529.reponame:Sistema de Gestión del Conocimiento ANLIS MALBRÁNinstname:Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"instacron:ANLISenginfo:eu-repo/semantics/openAccess2025-09-29T14:29:54Zoai:sgc.anlis.gob.ar:Publications/123456789/241Institucionalhttp://sgc.anlis.gob.ar/Organismo científico-tecnológicoNo correspondehttp://sgc.anlis.gob.ar/oai/biblioteca@anlis.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:a2025-09-29 14:29:55.178Sistema de Gestión del Conocimiento ANLIS MALBRÁN - Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"false
dc.title.none.fl_str_mv Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease
title Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease
spellingShingle Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease
Sosa-Estani, Sergio
Enfermedad de Chagas
Nitroimidazoles
Tripanocidas
Método Doble Ciego
Niño
title_short Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease
title_full Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease
title_fullStr Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease
title_full_unstemmed Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease
title_sort Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease
dc.creator.none.fl_str_mv Sosa-Estani, Sergio
Segura, Elsa L.
Ruiz, Andrés Mariano
Velazquez, Elsa
Porcel, Betina Mabel
Yampotis, Cristina
author Sosa-Estani, Sergio
author_facet Sosa-Estani, Sergio
Segura, Elsa L.
Ruiz, Andrés Mariano
Velazquez, Elsa
Porcel, Betina Mabel
Yampotis, Cristina
author_role author
author2 Segura, Elsa L.
Ruiz, Andrés Mariano
Velazquez, Elsa
Porcel, Betina Mabel
Yampotis, Cristina
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Enfermedad de Chagas
Nitroimidazoles
Tripanocidas
Método Doble Ciego
Niño
topic Enfermedad de Chagas
Nitroimidazoles
Tripanocidas
Método Doble Ciego
Niño
dc.description.none.fl_txt_mv A double-blind, randomized, clinical field trial was designed to test the efficacy and tolerance of a specific drug treatment in children in the indeterminate phase of infection by Trypanosoma cruzi. Children were treated with benznidazole at a dose of 5 mg/kg/day for 60 days or placebo and followed-up for 48 months. The treated children showed a significant decrease in geometric mean titers of antibodies against T. cruzi measured by indirect hemagglutination, indirect immunofluorescence, and ELISA. After a four year follow-up, 62% of the benznidazole- treated children and no placebo-treated child were seronegative for T. cruzi when tested by an ELISA using a T. cruzi flagellar calcium-binding protein (F29). Xenodiagnosis carried out after 48 months of follow-up was positive in 4.7% of the benznidazole-treated children and in 51.2% of the placebo-treated children. These results show the tolerance to and efficacy of benznidazole against T. cruzi in seropositive children six to 12 years of age. We used an early serologic marker of cure after treatment, consisting of a recombinant antigen implemented in a rapid, conventional serologic procedure.
Fil: Sosa-Estani, Sergio. ANLIS Dr.C.G.Malbrán. Centro Nacional de Diagnóstico e Investigación en Endemo-Epidemias; Argentina.
Fil: Segura, Elsa Leonor. ANLIS Dr.C.G.Malbrán; Argentina.
Fil: Ruiz, Andres Mariano. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología Dr. Mario Fatala Chaben; Argentina.
Fil: Velazquez, Elsa. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología Dr. Mario Fatala Chaben; Argentina.
Fil: Porcel, Betina Mabel. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología Dr. Mario Fatala Chaben; Argentina.
Fil: Yampotis, Cristina. Hospital San Roque; Argentina.
description A double-blind, randomized, clinical field trial was designed to test the efficacy and tolerance of a specific drug treatment in children in the indeterminate phase of infection by Trypanosoma cruzi. Children were treated with benznidazole at a dose of 5 mg/kg/day for 60 days or placebo and followed-up for 48 months. The treated children showed a significant decrease in geometric mean titers of antibodies against T. cruzi measured by indirect hemagglutination, indirect immunofluorescence, and ELISA. After a four year follow-up, 62% of the benznidazole- treated children and no placebo-treated child were seronegative for T. cruzi when tested by an ELISA using a T. cruzi flagellar calcium-binding protein (F29). Xenodiagnosis carried out after 48 months of follow-up was positive in 4.7% of the benznidazole-treated children and in 51.2% of the placebo-treated children. These results show the tolerance to and efficacy of benznidazole against T. cruzi in seropositive children six to 12 years of age. We used an early serologic marker of cure after treatment, consisting of a recombinant antigen implemented in a rapid, conventional serologic procedure.
publishDate 1998
dc.date.none.fl_str_mv 1998
dc.type.none.fl_str_mv info:ar-repo/semantics/articulo
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv 1476-1645
http://sgc.anlis.gob.ar/handle/123456789/241
http://www.ajtmh.org/content/59/4/526.full.pdf+html
identifier_str_mv 1476-1645
url http://sgc.anlis.gob.ar/handle/123456789/241
http://www.ajtmh.org/content/59/4/526.full.pdf+html
dc.language.none.fl_str_mv eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv The American Journal of Tropical Medicine and Hygiene, 1998, 59(4), 526–529.
reponame:Sistema de Gestión del Conocimiento ANLIS MALBRÁN
instname:Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
instacron:ANLIS
reponame_str Sistema de Gestión del Conocimiento ANLIS MALBRÁN
collection Sistema de Gestión del Conocimiento ANLIS MALBRÁN
instname_str Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
instacron_str ANLIS
institution ANLIS
repository.name.fl_str_mv Sistema de Gestión del Conocimiento ANLIS MALBRÁN - Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
repository.mail.fl_str_mv biblioteca@anlis.gov.ar
_version_ 1844621851244888064
score 12.559606

Publicaciones similares